免疫检查点抑制剂在非小细胞肺癌临床诊疗中的研究进展

Research progress of immune checkpoint inhibitors in clinical diagnosis and treatment of non-small cell lung cancer

肺癌是目前世界上发病率和死亡率最高的恶性肿瘤,其中主要的类型是非小细胞肺癌(NSCLC)。免疫检查点抑制剂是恶性肿瘤治疗发展史上里程碑式的发现,给很多恶性肿瘤患者提供了新的治疗选择。文章总结了免疫检查点抑制剂在NSCLC临床诊疗中的研究进展,探讨了药物作用的原理、不同临床分期NSCLC的诊疗差别以及未来的研究方向,为临床医师在治疗过程中使用免疫检查点抑制剂提供参考。

Lung cancer is currently the malignant tumor with the highest morbidity and mortality in the world,and the main type is non-small cell lung cancer.Immune checkpoint inhibitor is a landmark discovery in the history of cancer treatment,which rewrites the history of cancer treatment,and improves the medical treatment of advanced tumors by a big step forward.The article summarizes the research progress of therapeutic drugs against anti-programmed cell death protein and programmed cell death protein ligand antibodies in the clinical diagnosis and treatment of non-small cell lung cancer.The principle of drug action,the differences in the diagnosis and treatment of non-small cell lung cancer in different clinical stages,and future research directions are discussed to provide the usage guidelines of immune checkpoint inhibitors for clinical oncologists.